Patents by Inventor Tamami UESHIMA

Tamami UESHIMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-Eva1 PROTEIN ANTIBODY
    Publication number: 20220332842
    Abstract: In order to provide an antibody having high therapeutic and prophylactic effects against cancer and the like, three types of mouse monoclonal antibodies were prepared which exhibit high affinities for a human-derived Eva1 protein. Moreover, constant regions of these antibodies were substituted with human-derived constant regions to also prepare chimeric antibodies. Further, these mouse antibodies and chimeric antibodies were found to have high ADCC and/or CDC activities. Furthermore, it was also revealed that administering these antibodies to mice having been subjected to melanoma cell administration suppresses the metastasis and the like of the cells to the lungs.
    Type: Application
    Filed: April 25, 2022
    Publication date: October 20, 2022
    Applicant: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Toshitada TAKEMORI, Mikako Shirouzu, Miho Tanaka, Tamami Ueshima, Toru Kondo
  • Anti-Eva1 protein antibody
    Patent number: 11339224
    Abstract: In order to provide an antibody having high therapeutic and prophylactic effects against cancer and the like, three types of mouse monoclonal antibodies were prepared which exhibit high affinities for a human-derived Eva1 protein. Moreover, constant regions of these antibodies were substituted with human-derived constant regions to also prepare chimeric antibodies. Further, these mouse antibodies and chimeric antibodies were found to have high ADCC and/or CDC activities. Furthermore, it was also revealed that administering these antibodies to mice having been subjected to melanoma cell administration suppresses the metastasis and the like of the cells to the lungs.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 24, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Toshitada Takemori, Mikako Shirouzu, Miho Tanaka, Tamami Ueshima, Toru Kondo
  • ANTI-EVA1 PROTEIN ANTIBODY
    Publication number: 20190256610
    Abstract: In order to provide an antibody having high therapeutic and prophylactic effects against cancer and the like, three types of mouse monoclonal antibodies were prepared which exhibit high affinities for a human-derived Eva1 protein. Moreover, constant regions of these antibodies were substituted with human-derived constant regions to also prepare chimeric antibodies. Further, these mouse antibodies and chimeric antibodies were found to have high ADCC and/or CDC activities. Furthermore, it was also revealed that administering these antibodies to mice having been subjected to melanoma cell administration suppresses the metastasis and the like of the cells to the lungs.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 22, 2019
    Applicant: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Toshitada TAKEMORI, Mikako SHIROUZU, Miho TANAKA, Tamami UESHIMA, Toru KONDO